A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3) - PRESERVE 3

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2021
This article has no abstract
Epistemonikos ID: 0237df2966b3111a9821d25037bedf5180b5f06b
First added on: Apr 17, 2025